Equities Analysts Offer Predictions for BDTX Q1 Earnings

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Investment analysts at Wedbush upped their Q1 2025 EPS estimates for Black Diamond Therapeutics in a research note issued to investors on Wednesday, March 19th. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of $0.92 for the quarter, up from their previous estimate of ($0.28). Wedbush currently has a “Outperform” rating and a $11.00 target price on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.30) per share. Wedbush also issued estimates for Black Diamond Therapeutics’ FY2025 earnings at $0.07 EPS.

A number of other research analysts have also weighed in on BDTX. HC Wainwright increased their price target on Black Diamond Therapeutics from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, March 18th. Stifel Nicolaus cut their target price on Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Black Diamond Therapeutics has a consensus rating of “Buy” and an average target price of $14.60.

Black Diamond Therapeutics Stock Down 5.3 %

NASDAQ BDTX opened at $1.78 on Monday. The business has a fifty day moving average of $2.16 and a 200-day moving average of $2.85. Black Diamond Therapeutics has a fifty-two week low of $1.59 and a fifty-two week high of $7.66. The stock has a market cap of $100.86 million, a price-to-earnings ratio of -1.34 and a beta of 2.52.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03.

Insider Buying and Selling at Black Diamond Therapeutics

In related news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the completion of the sale, the insider now directly owns 2,733,547 shares of the company’s stock, valued at $5,658,442.29. This represents a 67.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 8.87% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Vestal Point Capital LP boosted its holdings in Black Diamond Therapeutics by 11.4% during the fourth quarter. Vestal Point Capital LP now owns 5,600,000 shares of the company’s stock valued at $11,984,000 after acquiring an additional 571,500 shares during the period. Squarepoint Ops LLC increased its position in shares of Black Diamond Therapeutics by 122.8% during the fourth quarter. Squarepoint Ops LLC now owns 131,874 shares of the company’s stock valued at $282,000 after purchasing an additional 72,688 shares during the period. Tang Capital Management LLC increased its holdings in Black Diamond Therapeutics by 51.1% in the 4th quarter. Tang Capital Management LLC now owns 2,070,209 shares of the company’s stock valued at $4,430,000 after buying an additional 700,000 shares during the period. Nuveen Asset Management LLC boosted its position in shares of Black Diamond Therapeutics by 12.8% during the 4th quarter. Nuveen Asset Management LLC now owns 201,535 shares of the company’s stock valued at $431,000 after acquiring an additional 22,802 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Black Diamond Therapeutics by 503.0% in the 4th quarter. Millennium Management LLC now owns 558,076 shares of the company’s stock worth $1,194,000 after purchasing an additional 465,531 shares during the last quarter. 95.47% of the stock is owned by hedge funds and other institutional investors.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.